VRTX — Vertex Pharmaceuticals Share Price
Last trade - 00:00- $125.74bn
- $119.74bn
- $11.02bn
- 92
- 18
- 79
- 68
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 25.96 | ||
| PEG Ratio (f) | 2.12 | ||
| EPS Growth (f) | 13.92% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 7.66 | ||
| Price to Tang. Book | 8.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 11.41 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.23% | ||
| Return on Equity | -3.15% | ||
| Operating Margin | -2.11% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6,205.68 | 7,574.4 | 8,930.7 | 9,869.2 | 11,020.1 | 11,970.4 | 13,134.93 | 21.5% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +128.04 | -12.47 | +47.66 | +19.63 | -0.3 | +14.03 | +13.71 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Directors
- Jeffrey Leiden CHM (65)
- Reshma Kewalramani PRE (48)
- Charles Wagner CFO (52)
- Stuart Arbuckle COO (55)
- Michael Parini EVP (46)
- David Altshuler EVP (56)
- Carmen Bozic EVP (58)
- Amit Sachdev EVP (53)
- Bastiano Sanna EVP (46)
- Ourania Tatsis EVP (51)
- Paul Silva SVP (54)
- Bruce Sachs LED (61)
- Sangeeta Bhatia IND (52)
- Lloyd Carney IND (59)
- Alan Garber IND (65)
- Terrence Kearney IND (66)
- Yuchun Lee IND (55)
- Margaret Mcglynn IND (61)
- Diana McKenzie IND (56)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- January 4th, 1989
- Public Since
- July 24th, 1991
- No. of Shareholders
- 101
- No. of Employees
- 6,100
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 257,080,844
- Address
- 50 Northern Avenue, BOSTON, 02210
- Web
- https://www.vrtx.com/
- Phone
- +1 6173416393
- Auditors
- Ernst & Young LLP
Latest News for VRTX
Upcoming Events for VRTX
Q1 2025 Vertex Pharmaceuticals Inc Earnings Release
Q1 2025 Vertex Pharmaceuticals Inc Earnings Call
Vertex Pharmaceuticals Inc Annual Shareholders Meeting
Vertex Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2025 Vertex Pharmaceuticals Inc Earnings Release
Similar to VRTX
Alnylam Pharmaceuticals
NASDAQ Global Select Market
Amgen
NASDAQ Global Select Market
Amneal Pharmaceuticals
NASDAQ Global Select Market
Amphastar Pharmaceuticals
NASDAQ Global Select Market
Apellis Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 23:57 UTC, shares in Vertex Pharmaceuticals are trading at $489.10. This share price information is delayed by 15 minutes.
Shares in Vertex Pharmaceuticals last closed at $489.10 and the price had moved by +24.42% over the past 365 days. In terms of relative price strength the Vertex Pharmaceuticals share price has outperformed the S&P500 Index by +16.99% over the past year.
The overall consensus recommendation for Vertex Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreVertex Pharmaceuticals does not currently pay a dividend.
Vertex Pharmaceuticals does not currently pay a dividend.
Vertex Pharmaceuticals does not currently pay a dividend.
To buy shares in Vertex Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $489.10, shares in Vertex Pharmaceuticals had a market capitalisation of $125.74bn.
Here are the trading details for Vertex Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: VRTX
Based on an overall assessment of its quality, value and momentum Vertex Pharmaceuticals is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Vertex Pharmaceuticals is $502.86. That is 2.81% above the last closing price of $489.10.
Analysts covering Vertex Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of $18.10 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vertex Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +12.21%.
As of the last closing price of $489.10, shares in Vertex Pharmaceuticals were trading +3.86% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Vertex Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is 25.96. The shares last closed at $489.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Vertex Pharmaceuticals' management team is headed by:
- Jeffrey Leiden - CHM
- Reshma Kewalramani - PRE
- Charles Wagner - CFO
- Stuart Arbuckle - COO
- Michael Parini - EVP
- David Altshuler - EVP
- Carmen Bozic - EVP
- Amit Sachdev - EVP
- Bastiano Sanna - EVP
- Ourania Tatsis - EVP
- Paul Silva - SVP
- Bruce Sachs - LED
- Sangeeta Bhatia - IND
- Lloyd Carney - IND
- Alan Garber - IND
- Terrence Kearney - IND
- Yuchun Lee - IND
- Margaret Mcglynn - IND
- Diana McKenzie - IND